Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 170

Sort by

Sort Order Select

Journal Articles

Phase 3 randomized study of teclistamab plus daratumumab versus investigator’s choice of daratumumab and dexamethasone with either pomalidomide or Bortezomib (DPd/DVd) in patients (Pts) with relapsed refractory multiple myeloma (RRMM): Results of majestec-3

Blood (2025) 146 (Supplement 2): LBA-6.

https://doi.org/10.1182/blood-2025-LBA-6

Published: 2025

Journal Articles

Innovative sdab-based CAR-T cells targeting BCMA outperform current CAR-T therapies for multiple myeloma

Vianca Ibarra-Garcia, Maria Erendira Calleja-Cervantes, Eva Molina, Franco Bernasconi-Bisio, Federica Rochira, Iñigo Azagra-Barber, Ines Ibañez-Sala, Saray Rodriguez-Diaz, Rebeca Martinez-Turrillas, Lucia Vanrell, Juan Lasarte, Ana Alfonso-Pierola, Paula Rodriguez-Otero, Jesus San-Miguel, Juan Roberto Rodriguez-Madoz, Antonio Pineda-Lucena, Felipe Prosper

Blood (2025) 146 (Supplement 1): 4072.

https://doi.org/10.1182/blood-2025-4072

Published: 2025

Journal Articles

Updated efficacy and safety results of JNJ-5322, a novel, next-generation BCMA×GPRC5D×CD3 trispecific antibody, in patients with Relapsed/Refractory multiple myeloma

Blood (2025) 146 (Supplement 1): 4042.

https://doi.org/10.1182/blood-2025-4042

Published: 2025

Journal Articles

Randomized phase II dose optimization study of inobrodib (CCS1477), in combination with pomalidomide and dexamethasone in relapsed/refractory multiple myeloma (RRMM)

Blood (2025) 146 (Supplement 1): 4035.

https://doi.org/10.1182/blood-2025-4035

Published: 2025

Journal Articles

Iberdomide plus daratumumab and dexamethasone (IberDd) in patients with newly diagnosed multiple myeloma by renal function: A subgroup analysis of the CC-220-MM-001 trial

Anna Sureda Balarí, Abdullah Khan, Albert Oriol, Mercedes Gironella Mesa, Faiz Anwer, Cristina Encinas, Brea Lipe, Paula Rodriguez-Otero, Ping Chen, Hongxia Lin, Kexin Jin, Thomas Solomon, Lilia Taningco, Olumoroti Aina, Paulo Maciag, Sagar Lonial

Blood (2025) 146 (Supplement 1): 5810.

https://doi.org/10.1182/blood-2025-5810

Published: 2025

Journal Articles

Validation of the High-Risk Consensus Genomic Staging System in Newly Diagnosed Multiple Myeloma

Blood (2025) 146 (Supplement 1): 922.

https://doi.org/10.1182/blood-2025-922

Published: 2025

Journal Articles

Transcriptional stratification reveals distinct molecular subtypes with treatment-specific outcomes in multiple myeloma patients from the GEM2017FIT trial

Blood (2025) 146 (Supplement 1): 496.

https://doi.org/10.1182/blood-2025-496

Published: 2025

Journal Articles

Belantamab mafodotin (belamaf) in combination with bortezomib, lenalidomide, and dexamethasone (VRd) for patients (pts) with transplant-ineligible (TI) newly diagnosed multiple myeloma (NDMM): A focus on treatment efficacy and management/resolution of ocular events in the Phase 1 dreamm-9 study

Blood (2025) 146 (Supplement 1): 5840.

https://doi.org/10.1182/blood-2025-5840

Published: 2025

Journal Articles

Talquetamab outcomes from practice outside of clinical trials: The bital study

María-Victoria Mateos, Marcos Lorenzo Perez, Ana Saus Carreres, Mario Arnao, Elena Fernández Poveda, Ana Pilar Gonzalez, Sunil Lakhwani, Juan Luis Reguera, Jose Maria Sanchez Pina, Ana Sánchez Quintana, Miriam Concepcion Gonzalez Pardo, María-Jesús Blanchard, Paula Rodriguez-Otero

Blood (2025) 146 (Supplement 1): 5827.

https://doi.org/10.1182/blood-2025-5827

Published: 2025

Journal Articles

Long-term progression-free survival benefit with ciltacabtagene autoleucel in standard-risk relapsed / refractory multiple myeloma

Blood (2025) 146 (Supplement 1): 94.

https://doi.org/10.1182/blood-2025-94

Published: 2025

Journal Articles

FAM46C/Tent5c inactivation accelerates multiple myeloma progression from early stages and remodels the bone marrow immune microenvironment in preclinical models

Blood (2025) 146 (Supplement 1): 1027.

https://doi.org/10.1182/blood-2025-1027

Published: 2025

Journal Articles

Phase 1 study of ktx-1001, a first-in-class oral MMSET/NSD2 inhibitor, demonstrates clinical activity in relapsed/refractory multiple myeloma

Blood (2025) 146 (Supplement 1): 250.

https://doi.org/10.1182/blood-2025-250

Published: 2025

Journal Articles

Single-cell DNA profiling unveils clonal evolution and identifies mechanisms of therapeutic resistance and progression in monoclonal gammopathies

Beñat Ariceta, Paula Aguirre-Ruiz, Andrea Castro, Diego Alignani, Saioa Vicente, Aitziber Lopez, Ana Alfonso-Pierola, Luis-Esteban Tamariz-Amador, Jesus San-Miguel, Paula Rodriguez-Otero, Felipe Prosper

Blood (2025) 146 (Supplement 1): 7445.

https://doi.org/10.1182/blood-2025-7445

Published: 2025

Journal Articles

Targeted long-read sequencing with adaptive sampling in multiple myeloma: A pilot study toward a unified diagnostic platform

Beñat Ariceta, Paula Aguirre-Ruiz, Andrea Castro, Patxi San Martin-Uriz, Saioa Vicente, Maria Jose Larrayoz, Luis-Esteban Tamariz-Amador, Ana Alfonso-Pierola, Jesus San-Miguel, Maria Calasanz, Paula Rodriguez-Otero, Felipe Prosper

Blood (2025) 146 (Supplement 1): 6121.

https://doi.org/10.1182/blood-2025-6121

Published: 2025

Journal Articles

Extended treatment-free hospitalization-free time and quality of life benefits with CAR T-cell therapy in subgroups of patients with relapsed/refractory MM: Insights from the KarMMa-3 trial

Krina Patel, Lin Wang, Rashmi Bhatnagar, Roland Marion Gallois, Martina Raggi, Sophie Hello, Paula Rodriguez-Otero

Blood (2025) 146 (Supplement 1): 5769.

https://doi.org/10.1182/blood-2025-5769

Published: 2025

Journal Articles

Virma epitranscriptomically regulates cell proliferation, apoptosis, and mitochondrial function via m6A in multiple myeloma

Estibaliz Urizar Compains, Naroa Barrena, Theodore Maximilian Nelson, Leire Garate, Estibaliz Miranda Elizalde, Juan Antonio Romero Torrecilla, Luis Vitores Valcárcel García, Marta Kulis, Elisa Garbayo Atienza, Maria José Blanco Prieto, Paula Rodriguez-Otero, Jose Martin-Subero, Christopher Mason, Edurne San José Enériz, Felipe Prosper, Xabier Agirre

Blood (2025) 146 (Supplement 1): 3255.

https://doi.org/10.1182/blood-2025-3255

Published: 2025

Journal Articles

Impact of tumor burden on the risk of cytokine release syndrome (CRS) in patients with multiple myeloma treated with elranatamab (ELRA) in combination with daratumumab (DARA) and lenalidomide (R) in the MagnetisMM-6 trial

Cyrille Touzeau, Hanlon Sia, Sebastian Grosicki, Paz Ribas, Carmine Liberatore, Paula Rodriguez-Otero, Suzanne Trudel, Takashi Ikeda, Antonio Lazzaro, Karen Gogat-Marchant, Sharon T. Sullivan, Domenico Cieri, Eric Leip, Meletios Dimopoulos

Blood (2025) 146 (Supplement 1): 2283.

https://doi.org/10.1182/blood-2025-2283

Published: 2025

Journal Articles

Impact of previous BCMA exposure: Evidence from practice outside of clinical trials to inform talquetamab sequencing

María-Jesús Blanchard, Marcos Lorenzo Perez, Ana Saus Carreres, Mario Arnao, Elena Fernández Poveda, Ana Pilar Gonzalez, Sunil Lakhwani, Juan Luis Reguera, Jose Maria Sanchez Pina, Ana Sánchez Quintana, Miriam Concepcion Gonzalez Pardo, María-Victoria Mateos, Paula Rodriguez-Otero

Blood (2025) 146 (Supplement 1): 2272.

https://doi.org/10.1182/blood-2025-2272

Published: 2025

Journal Articles

Efficacy and safety of isa-vrd in elderly patients with or without frailty criteria: Pooled analysis of imroz and phase 1b studies in newly diagnosed multiple myeloma patients

Enrique Ocio, Aurore Perrot, Jesus San-Miguel, Lionel Karlin, Joaquin Martinez-Lopez, Sara Bringhen, Paula Rodriguez-Otero, Mohamad Mohty, Robert Orlowski, Meletios Dimopoulos, Xavier Leleu, María-Victoria Mateos, Philippe Moreau, Sandrine Macé, Ecrem Kodas, Christine Tekle, Umer Khan, Corina Oprea, Thierry Facon

Blood (2025) 146 (Supplement 1): 2267.

https://doi.org/10.1182/blood-2025-2267

Published: 2025

Journal Articles

Early rescue intervention with daratumumab, pomalidomide and dexamethasone (DPd) in high-risk smoldering myeloma (HR-SMM) patients included in the GEM-CESAR treated with carfilzomib, lenalidomide and dexamethasone (KRd)- autologous stem cell transplantation (ASCT)-krd-rd

Blood (2025) 146 (Supplement 1): 371.

https://doi.org/10.1182/blood-2025-371

Published: 2025

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Phase 3 randomized study of teclistamab plus daratumumab versus investigator’s choice of daratumumab and dexamethasone with either pomalidomide or Bortezomib (DPd/DVd) in patients (Pts) with relapsed refractory multiple myeloma (RRMM): Results of majestec-3

Innovative sdab-based CAR-T cells targeting BCMA outperform current CAR-T therapies for multiple myeloma

Updated efficacy and safety results of JNJ-5322, a novel, next-generation BCMA×GPRC5D×CD3 trispecific antibody, in patients with Relapsed/Refractory multiple myeloma

Randomized phase II dose optimization study of inobrodib (CCS1477), in combination with pomalidomide and dexamethasone in relapsed/refractory multiple myeloma (RRMM)

Iberdomide plus daratumumab and dexamethasone (IberDd) in patients with newly diagnosed multiple myeloma by renal function: A subgroup analysis of the CC-220-MM-001 trial

Validation of the High-Risk Consensus Genomic Staging System in Newly Diagnosed Multiple Myeloma

Transcriptional stratification reveals distinct molecular subtypes with treatment-specific outcomes in multiple myeloma patients from the GEM2017FIT trial

Belantamab mafodotin (belamaf) in combination with bortezomib, lenalidomide, and dexamethasone (VRd) for patients (pts) with transplant-ineligible (TI) newly diagnosed multiple myeloma (NDMM): A focus on treatment efficacy and management/resolution of ocular events in the Phase 1 dreamm-9 study

Talquetamab outcomes from practice outside of clinical trials: The bital study

Long-term progression-free survival benefit with ciltacabtagene autoleucel in standard-risk relapsed / refractory multiple myeloma

FAM46C/Tent5c inactivation accelerates multiple myeloma progression from early stages and remodels the bone marrow immune microenvironment in preclinical models

Phase 1 study of ktx-1001, a first-in-class oral MMSET/NSD2 inhibitor, demonstrates clinical activity in relapsed/refractory multiple myeloma

Single-cell DNA profiling unveils clonal evolution and identifies mechanisms of therapeutic resistance and progression in monoclonal gammopathies

Targeted long-read sequencing with adaptive sampling in multiple myeloma: A pilot study toward a unified diagnostic platform

Extended treatment-free hospitalization-free time and quality of life benefits with CAR T-cell therapy in subgroups of patients with relapsed/refractory MM: Insights from the KarMMa-3 trial

Virma epitranscriptomically regulates cell proliferation, apoptosis, and mitochondrial function via m6A in multiple myeloma

Impact of tumor burden on the risk of cytokine release syndrome (CRS) in patients with multiple myeloma treated with elranatamab (ELRA) in combination with daratumumab (DARA) and lenalidomide (R) in the MagnetisMM-6 trial

Impact of previous BCMA exposure: Evidence from practice outside of clinical trials to inform talquetamab sequencing

Efficacy and safety of isa-vrd in elderly patients with or without frailty criteria: Pooled analysis of imroz and phase 1b studies in newly diagnosed multiple myeloma patients

Early rescue intervention with daratumumab, pomalidomide and dexamethasone (DPd) in high-risk smoldering myeloma (HR-SMM) patients included in the GEM-CESAR treated with carfilzomib, lenalidomide and dexamethasone (KRd)- autologous stem cell transplantation (ASCT)-krd-rd

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only